Terms: = Lung cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
50 results:
1. The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer.
Xu W; Liu X; Yan C; Abdurahmane G; Lazibiek J; Zhang Y; Cao M
Sci Rep; 2024 Mar; 14(1):7568. PubMed ID: 38555313
[TBL] [Abstract] [Full Text] [Related]
2. Drug-induced interstitial lung disease: a narrative review of a clinical conundrum.
Harrison M; Kavanagh G; Corte TJ; Troy LK
Expert Rev Respir Med; 2024; 18(1-2):23-39. PubMed ID: 38501199
[TBL] [Abstract] [Full Text] [Related]
3. Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.
Assié JB; Jean D
Expert Opin Ther Targets; 2023; 27(11):1059-1069. PubMed ID: 37902459
[TBL] [Abstract] [Full Text] [Related]
4. T Cells in Colorectal cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431
[TBL] [Abstract] [Full Text] [Related]
5. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract] [Full Text] [Related]
6. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted car T-cell therapy: a case report.
Wang Y; Zhao Y; Li M; Hou H; Jian Z; Li W; Li P; Ma F; Liu M; Liu H; Xue H
Front Immunol; 2023; 14():1180001. PubMed ID: 37256142
[TBL] [Abstract] [Full Text] [Related]
7. Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway.
Wang C; Zhang L; Cao M; Fu Z; Wang H; Zhang S; Zhu K; Hou Z; Cui J; Yue P; Guo H; Zhang T
FASEB J; 2023 Jun; 37(6):e22943. PubMed ID: 37104068
[TBL] [Abstract] [Full Text] [Related]
8. IL-18-secreting car T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE; Khan JF; Godfrey WD; Lopez AV; Ciampricotti M; Rudin CM; Brentjens RJ
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36951942
[TBL] [Abstract] [Full Text] [Related]
9. Human antibodies targeting ENPP1 as candidate therapeutics for cancers.
Chu X; Baek DS; Li W; Shyp T; Mooney B; Hines MG; Morin GB; Sorensen PH; Dimitrov DS
Front Immunol; 2023; 14():1070492. PubMed ID: 36761762
[TBL] [Abstract] [Full Text] [Related]
10. Engineering c-Met-car NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma.
Peng Y; Zhang W; Chen Y; Zhang L; Shen H; Wang Z; Tian S; Yang X; Cui D; He Y; Chang X; Feng Z; Tang Q; Mao Y
Pharmacol Res; 2023 Feb; 188():106656. PubMed ID: 36640859
[TBL] [Abstract] [Full Text] [Related]
11. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract] [Full Text] [Related]
12. Holistic immunomodulation for small cell lung cancer.
Leung EL; Fan XX; Huang JM; Huang C; Lin H; Cao YB
Semin Cancer Biol; 2023 Jan; 88():96-105. PubMed ID: 36470543
[TBL] [Abstract] [Full Text] [Related]
13. Gastrointestinal toxicity of systemic oncology immunotherapy.
Bureš J; Kohoutová D; Zavoral M
Klin Onkol; 2022; 35(5):346-357. PubMed ID: 36443091
[TBL] [Abstract] [Full Text] [Related]
14. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy.
Okita R; Okada M; Inokawa H; Murakami T; Ikeda E
Surg Oncol; 2022 Aug; 43():101813. PubMed ID: 35816852
[TBL] [Abstract] [Full Text] [Related]
16. Correlation between C-reactive protein/albumin ratio and prognosis in patients with lung adenocarcinoma.
Jia-Min Z; Wei D; Ye L; Xiang-Tao P
J Int Med Res; 2022 Jun; 50(6):3000605221105372. PubMed ID: 35730330
[TBL] [Abstract] [Full Text] [Related]
17. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (car-T) Therapy in lung cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract] [Full Text] [Related]
18. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
Perera ND; Mansfield AS
Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
[TBL] [Abstract] [Full Text] [Related]
19. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated car-T cell migration.
Li H; Harrison EB; Li H; Hirabayashi K; Chen J; Li QX; Gunn J; Weiss J; Savoldo B; Parker JS; Pecot CV; Dotti G; Du H
Nat Commun; 2022 Apr; 13(1):2154. PubMed ID: 35443752
[TBL] [Abstract] [Full Text] [Related]
20. [Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell lung cancer].
Zhang H; Li X; Li X; Su Y
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):790-795. PubMed ID: 34802211
[TBL] [Abstract] [Full Text] [Related]
[Next]
